ARKG news

ARK Genomic Revolution · Healthcare · United States · Genomics & Biotech Innovation

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Seeking Alpha · 28 Oct 2026, 20:19 UTC
10x Genomics: Atera Takes Off, But Valuation Flies Too High (NASDAQ:TXG) | Seeking Alpha
9.4% of ARKG
Investing.com · 28 Oct 2026, 14:08 UTC
Why is Twist Bioscience stock surging today? By Investing.com
7.7% of ARKG
wallstreet:online · 28 Oct 2026, 12:05 UTC
Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
7.7% of ARKG
24/7 Wall St. · 28 Oct 2026, 19:24 UTC
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
4.7% of ARKG
Where to buy ARKG
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Scienmag: Latest Science and Health News · 28 Oct 2026, 18:47 UTC
Nanopore Sequencing Delivers Full Pediatric Brain Tumor Workup in a Single
4.7% of ARKG
Quartz · 28 Oct 2026, 16:16 UTC
Best-selling drugs 2026: 7 of the top 10 by 2025 sales
4.7% of ARKG
Where to buy ARKG
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 28 Oct 2026, 15:55 UTC
Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) | Seeking Alpha
4.7% of ARKG
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
4.7% of ARKG
Benzinga · 28 Oct 2026, 13:25 UTC
Eli Lilly Says Retatrutide Delivers More Than Double Ozempic's Weight Loss in Late-Stage Diabetes Trial -
4.7% of ARKG
24/7 Wall St. · 28 Oct 2026, 12:14 UTC
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
4.7% of ARKG
Market Screener · 28 Oct 2026, 12:07 UTC
Eli Lilly And Company Announces Positive Topline Results From TRANSCEND-T2D-2 Phase 3 Trial Of Retatrutide In Adults With Type 2 Diabetes
4.7% of ARKG
Benzinga · 28 Oct 2026, 10:04 UTC
Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings - Eli Lilly (NYSE:LLY)
4.7% of ARKG
Yahoo! Finance · 28 Oct 2026, 07:29 UTC
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
4.7% of ARKG
24/7 Wall St. · 27 Oct 2026, 13:28 UTC
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
6.6% of ARKG
www.theepochtimes.com · 28 Oct 2026, 00:00 UTC
Judge Declines to Block Eli Lilly Weight-Loss Drug Ads in Dispute With Novo Nordisk
4.7% of ARKG
Business Insider · 28 Oct 2026, 00:00 UTC
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
4.7% of ARKG
Yahoo! Finance · 27 Oct 2026, 23:28 UTC
$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today
4.7% of ARKG
The Boston Globe · 27 Oct 2026, 22:09 UTC
MGH, Brigham, other hospitals sue Eli Lilly, alleging 'extortion' in drug discount program
4.7% of ARKG
Seeking Alpha · 27 Oct 2026, 22:08 UTC
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick (NVO) | Seeking Alpha
4.7% of ARKG
Investing.com · 27 Oct 2026, 20:47 UTC
Eli Lilly international business chief Jonsson to retire; Yuffa to head global markets unit By Reuters
4.7% of ARKG

ARKG news

Where to buy ARKG

Where to buy ARKG